Analysis
Baba, an applied-AI company modernizing the Medicare and Medicaid experience, raised a $40 million Series A led by FirstMark Capital, with CVS Health Ventures and Valtruis joining as new investors and General Catalyst, Genius Ventures and Ground Up Ventures returning, according to the company's announcement. Founder and CEO Connor Sweeney's company pairs licensed clinicians, care coordinators and AI to help patients and families access, afford and track care -- each patient gets a dedicated team covering specialist visits, hospital discharges, behavioral health, in-home support and non-medical needs like housing and transportation.
Baba says it has supported more than 10,000 patients and families across the U.S., with more than 100,000 families on its waiting list -- a 10-to-1 gap between demand and current capacity that a $40 million round is unlikely to close on its own. The company plans to use the new capital to expand its clinical care teams, advance its AI research, serve more health plans and accelerate value-based care arrangements.
A government contract, not just a product, is the real asset here
In June, the Centers for Medicare & Medicaid Services selected Baba for the ACCESS Model, the CMS Innovation Center's 10-year test of technology-supported chronic care, across all four of its clinical tracks: early cardio-kidney-metabolic, cardio-kidney-metabolic, musculoskeletal and behavioral health. That selection is a meaningful distribution advantage over smaller care-navigation rivals, but it's worth remembering the ACCESS Model is a pilot program with a defined, if long, 10-year horizon -- not a permanent reimbursement guarantee, and CMS test programs have been narrowed or ended before.
Baba also published BabaBench, an arXiv benchmark now accepted to a NeurIPS workshop, that tests whether AI agents can complete long-horizon patient-advocacy tasks like paperwork, insurer calls and billing follow-up -- an attempt to put empirical numbers behind a category where most startups' AI claims go untested by outside researchers.
The company competes most directly with Abridge, Commure and Sword Health, all building some version of AI-assisted clinical workflow or care navigation; Baba's specific bet is that owning the Medicare and Medicaid patient relationship end-to-end, rather than selling software to providers, is the more defensible position. With nearly 70 million Americans on Medicare and more than 63 million family caregivers nationally -- up 20 million over the past decade, per the company -- the addressable population is real. Whether a $40 million round, even with CVS Health Ventures' strategic insurer backing, is enough to scale clinician-staffed care teams fast enough to meaningfully dent that 100,000-family waiting list remains the open question.
